Millennium Management
IDXG

Millennium Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Millennium Management’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,725
Closed -$57K – 4415
2018
Q3 		$57K Buy
+3,725
New +$44.9K ﹤0.01% 3798

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Millennium Management's IDXG Position: Q4 2018 in Review

Millennium Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2018, closing a stake of 3,725 shares — an estimated $57K sold.

Millennium Management first reported a position in IDXG in Q3 2018 and held it in 1 quarter. The position peaked at $57K in Q3 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q4 2018.

  • Millennium Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Millennium Management sold 3,725 Interpace Biosciences, Inc. Common Stock shares in Q4 2018, an estimated $57K.
  • Millennium Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Millennium Management's Interpace Biosciences, Inc. Common Stock position peaked at $57K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2018.

Based on Millennium Management's 13F filing for Q4 2018, filed 14 Feb 2019.